WLWu Liu

Wu Liu

*This is an algorithmically generated author record based on publicly available information.

Wu Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Liu

    Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China

    1 shared publication
  • Bingfeng Han

    Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

    1 shared publication
  • Fuqiang Cui

    Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, China

    1 shared publication
  • Hanyu Liu

    Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China

    1 shared publication
  • Juan Du

    Department of Laboratorial Science and Technology and Vaccine Research Center, School of Public Health, Peking University, Beijing, China

    1 shared publication
  • Shuai Wang

    National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products

    1 shared publication

Latest Publications

  • Open Access

    12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

    by Bingfeng Han, Wu Liu, Juan Du, Hanyu Liu, Tianshuo Zhao, Shubo Yang, Shuai Wang, Sihui Zhang, Bei Liu, Yaqiong Liu, et al.

    Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.